August 19, 2026
Who decides in the EU?
Out of five Croatians in Brussels, roughly one in five Croatians decided who would speak for the other four in…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
July 21, 2026
Germany goes to Bangalore: Formycon’s India deal is the latest sign that biosimilar manufacturing is moving east — permanently
A Munich-based biosimilar developer just signed a strategic manufacturing partnership with an Indian CDMO. According to industry analysts, it is not the first such deal, and it will not be the last. The question is what Europe gets — and what it gives up — as the shift accelerates?
July 21, 2026
How the Hormuz blockade became a prolonged war: pharma’s supply nightmare deepens as truce fails and strait closes again
The 21-mile-wide waterway that supplies Europe’s medicine cabinet is not reopening — it is effectively closed once more, live maritime tracking data and intelligence reports show. The crisis that began in February has evolved into an active theatre of war with no clear end in sight.
July 13, 2026
Poolbeg doses first patient in its CRS prevention trial, but the real test is n=30
Poolbeg Pharma (AIM: POLB) said on 13 July that the first patient has been dosed in its POLB 001 TOPICAL trial, according to the company’s RNS statement, and that University College London Hospital has now also been activated as a clinical trial site, with additional sites expected to open imminently. Investor reaction will hinge less on the milestone itself — dosing a first patient is table stakes for any trial — and more on what happens over the next six to eight weeks, since interim data is still on track for late summer.
April 20, 2026
The Rerouting of Europe‘s medicine cabinet: How the Iran war is reshaping pharmaceutical supply chains
By Pharmaceutical Daily Editorial Staff As the conflict in the Middle East enters its second month, the pharmaceutical industry across…
March 11, 2026
Faron’s €40 million lifeline: fully covered, but shareholders have weeks to decide
The Finnish biotech is going back to shareholders with a fully covered offering, aiming to fund a pivotal Phase II trial in high-risk myelodysplastic syndrome — and postponing its AGM for reasons that are anything but routine
March 10, 2026
Sandoz bets on its own new biosimilar unit with a veteran hire
A structural reorganization and a key appointment reveal a company that has moved beyond proving itself and is now building for dominance
March 6, 2026
The quiet revolution in heart disease: How siRNA is becoming cardiology’s most powerful new weapon
The quiet revolution in heart disease: How siRNA is becoming cardiology’s most powerful new weapon
March 3, 2026
UroGen lands $250M despite $153M loss — Are lenders right to bet on bladder cancer’s next blockbuster?
BioPharma Credit gets a bigger slice — and a $3M fee — as UroGen bets big on ZUSDURI
March 3, 2026
Germany Goes to Beijing: What the Merz-Xi summit means for pharma and life sciences
CEO of Leica Microsystems, a Danaher company — one of the few life sciences representatives in a room otherwise dominated by automotive and industrial giants.